Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in ...
US-based Elixir Medical has announced positive one-year results from the DESolve Nx international pivotal clinical trial for the CE Mark-approved, fully bioresorbable DESolve Novolimus eluting coronary scaffold system. At one year, the ...
Tags: Elixir Medical, NX Clinical Trial
US-based medical devices developer Elixir Medical has announced that the results of its CE Mark-approved DESyne BD Novolimus Eluting Coronary Stent System with biodegradable polymer coating were outstanding. Its CE Mark-approved DESyne BD ...
Elixir Medical has gained CE Mark approval for its DESyne BD Novolimus Eluting Coronary Stent System with biodegradable polymer coating. The Elixir DESyne BD stent leverages the technology that enables an ultrathin (< 3 microns) polymer ...
Tags: Elixir Medical, Elixir DESyne BD stent, biodegradable polymer coating